Physician profile
Sandra Chaparro
NPI 1043301997
$14,917.93
in general payments reported to CMS, 2019-2025
26 companies · $10K in 2025
The $10K reported for 2025 was more than what 77% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $464 · 2021: $514 · 2022: $897 · 2023: $1,168 · 2024: $748 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,750 · Food and Beverage: $4,203 · Travel and Lodging: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,750.00 |
| Food and Beverage | $4,203.35 |
| Travel and Lodging | $1,325.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $8,612.15 | 2021-2025 | Amvuttra |
| Abbott Laboratories | $1,260.72 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Navitor |
| Boston Scientific Corporation | $839.48 | 2021-2025 | Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $753.81 | 2019-2025 | Uptravi, Opsumit |
| Impulse Dynamics (USA) INC. | $741.17 | 2019-2024 | Optimizer, Optimizer |
| Medtronic, INC. | $575.67 | 2022-2025 | Symplicity G3, Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Abiomed | $313.32 | 2020-2025 | |
| Akcea Therapeutics, INC. | $259.89 | 2019-2020 | |
| Cardiac Dimensions, INC. | $226.18 | 2023 | |
| Medtronic Vascular, INC. | $200.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $174.58 | 2021-2025 | Wainua |
| Atricure, INC. | $166.00 | 2023 | |
| Novo Nordisk INC | $159.63 | 2024-2025 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $153.38 | 2025 | Mitris Resilia Mitral Valve |
| Lexicon Pharmaceuticals, INC. | $119.70 | 2024 | Inpefa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.27 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.37 | 2023-2024 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $41.76 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $37.43 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $31.66 | 2022 | |
| United Therapeutics Corporation | $29.18 | 2024 | Remodulin |
| Endotronix, INC. | $26.74 | 2024-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.91 | 2020 | |
| Livanova USA, INC. | $15.59 | 2019 | |
| Kestra Medical Technology Services, INC. | $14.60 | 2024 | Assure Wcd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Chaparro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.